Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Dow
Merck
Boehringer Ingelheim
McKesson

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ERGOCALCIFEROL

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Ergocalciferol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00114556 The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients Completed Novartis Phase 4 2000-02-01 Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess osteoporosis therapies in this system may provide useful information for osteoporosis management in general. Hypotheses: 1. That treatment with the bisphosphonate, zoledronate, at the time of liver transplantation and at 1 month post-transplantation will prevent the early transplant-related bone loss (measured by bone densitometry and biochemical bone markers at 3 months) seen in patients who are not treated with a bisphosphonate 2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration of 12 months will result in further improvements in bone density beyond that seen at 3 months 3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not prevent marked bone loss following transplantation.
NCT00114556 The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients Completed Royal Prince Alfred Hospital, Sydney, Australia Phase 4 2000-02-01 Following liver transplantation, rapid bone loss occurs, particularly within the first 6 months post-transplant. This may be associated with fractures, most notable vertebral. The ability to assess osteoporosis therapies in this system may provide useful information for osteoporosis management in general. Hypotheses: 1. That treatment with the bisphosphonate, zoledronate, at the time of liver transplantation and at 1 month post-transplantation will prevent the early transplant-related bone loss (measured by bone densitometry and biochemical bone markers at 3 months) seen in patients who are not treated with a bisphosphonate 2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration of 12 months will result in further improvements in bone density beyond that seen at 3 months 3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not prevent marked bone loss following transplantation.
NCT00157066 Effects of Vitamin D Supplementation on Antimycobacterial Immunity Completed Department of Clinical Biochemistry, Homerton Hospital, London E9 6SR, UK N/A 2002-12-01 The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
NCT00157066 Effects of Vitamin D Supplementation on Antimycobacterial Immunity Completed Environmental Health Department, London Borough of Newham, London E15 4SF, UK N/A 2002-12-01 The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
NCT00157066 Effects of Vitamin D Supplementation on Antimycobacterial Immunity Completed Imperial College London N/A 2002-12-01 The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
NCT00157066 Effects of Vitamin D Supplementation on Antimycobacterial Immunity Completed Newham Chest Clinic, London E7 8QP, UK N/A 2002-12-01 The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ergocalciferol

Condition Name

Condition Name for Ergocalciferol
Intervention Trials
Vitamin D Deficiency 12
Inflammation 3
Ergocalciferol 2
Nephrolithiasis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ergocalciferol
Intervention Trials
Vitamin D Deficiency 15
Kidney Diseases 7
Renal Insufficiency, Chronic 7
Inflammation 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ergocalciferol

Trials by Country

Trials by Country for Ergocalciferol
Location Trials
United States 24
Saudi Arabia 4
United Kingdom 2
Thailand 2
Israel 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ergocalciferol
Location Trials
New York 5
California 3
Massachusetts 3
North Carolina 1
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ergocalciferol

Clinical Trial Phase

Clinical Trial Phase for Ergocalciferol
Clinical Trial Phase Trials
Phase 4 14
Phase 3 4
Phase 2/Phase 3 2
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ergocalciferol
Clinical Trial Phase Trials
Completed 18
Recruiting 6
Not yet recruiting 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ergocalciferol

Sponsor Name

Sponsor Name for Ergocalciferol
Sponsor Trials
King Faisal Specialist Hospital & Research Center 3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2
Albert Einstein College of Medicine of Yeshiva University 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ergocalciferol
Sponsor Trials
Other 53
U.S. Fed 5
Industry 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Medtronic
Dow
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.